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et al. now show that this regulation is
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Thyroid-stimulating hormone (TSH; thyrotropin) is a
glycoprotein secreted from the pituitary gland. Pars
distalis-derived TSH (PD-TSH) stimulates the thyroid
gland to produce thyroid hormones (THs), whereas
pars tuberalis-derivedTSH (PT-TSH)actson thehypo-
thalamus to regulate seasonal physiology and be-
havior. However, it had not been clear how these two
TSHs avoid functional crosstalk. Here, we show that
this regulation ismediatedby tissue-specificglycosyl-
ation.AlthoughPT-TSH is released into thecirculation,
it does not stimulate the thyroid gland. PD-TSH is
known to have sulfated biantennary N-glycans, and
sulfated TSH is rapidly metabolized in the liver. In
contrast, PT-TSH has sialylated multibranched N-gly-
cans; in the circulation, it forms the macro-TSH com-
plex with immunoglobulin or albumin, resulting in the
loss of its bioactivity. Glycosylation is fundamental to
awide rangeof biological processes. This report dem-
onstrates its involvement in preventing functional
crosstalk of signaling molecules in the body.
INTRODUCTION
Thyroid-stimulating hormone (TSH) (thyrotropin) is a pituitary
hormone that stimulates the thyroid gland to produce thyroidChormones (THs) (Szkudlinski et al., 2002). TSH is a noncovalently
linked heterodimeric glycoprotein consisting of a and b subunits.
The a subunit is common to other glycoprotein hormones such
as luteinizing hormone (LH) and follicle-stimulating hormone
(FSH), whereas the b subunit is unique to each hormone (Pierce
and Parsons, 1981). TSH is synthesized in thyrotrophs of the
pars distalis (PD) of the pituitary gland (Magner, 1990) (Fig-
ure S1A). Synthesis and secretion of PD-TSH are positively regu-
lated by hypothalamic thyrotropin-releasing hormone (TRH).
Circulating PD-TSH acts on thyrocytes through the TSH receptor
(TSHR) to stimulate synthesis and release of THs, and circulating
TH inhibits PD-TSH by a negative-feedback loop (Szkudlinski
et al., 2002). In addition to this well-known action, an unexpected
function of this molecule was recently discovered: TSH derived
from the pars tuberalis (PT) of the pituitary gland (PT-TSH) is a
primary factor regulating seasonality (Hanon et al., 2008; Nakao
et al., 2008; Ono et al., 2008). Various physiological and behav-
ioral activities, such as reproduction andmigration, are regulated
by changes in day length. Long-day (LD) stimulus induces the
synthesis of PT-TSH, which acts on TSHR expressed in ependy-
mal cells within the mediobasal hypothalamus (MBH) to induce
expression of the Dio2 gene. Dio2 encodes type 2 deiodinase,
a TH-activating enzyme, which converts the precursor thyroxine
(T4) to bioactive triiodothyronine (T3) within the MBH, serving as
the key regulator of seasonality (Yoshimura et al., 2003).
The PT surrounds the hypophysial stalk and extends along the
ventral surface of the median eminence (Wittkowski et al., 1999)
(Figure S1A). The pituitary gland receives blood supply via the
hypothalamohypophysial portal circulation: capillaries arisingell Reports 9, 801–809, November 6, 2014 ª2014 The Authors 801
Figure 1. PT-TSH Secreted into the Peripheral Circulation Has Little
Bioactivity
(A–D) Effects of melatonin on TSH concentration in PT (A), PD (B), and serum
(C) and on serum T4 level (D). *p < 0.05; **p < 0.01 (t test, n = 6–12).
(E–G) Effects of changing day length and T3 administration on TshbmRNA (E),
TSH concentration in PD and PT (F), and serum TSH and T4 levels (G). T3, daily
T3 administration. *p < 0.05; **p < 0.01;
##p < 0.01 versus smallest value
(ANOVA, Fisher’s least significant difference post hoc test, n = 5–9). Values are
means ± SEM. Scale bars, 200 mm.
802 Cell Reports 9, 801–809, November 6, 2014 ª2014 The Authorsfrom the primary plexus project down the PT to form the portal
veins, and a secondary capillary plexus arising from the portal
vein supplies the PD before draining into the general circulation.
Previously, it had been unclear how PD-TSH and PT-TSH avoid
functional crosstalk and therebymaintain their distinct functions.
Here we report that tissue-specific glycosylation is central to this
mechanism.
RESULTS
PT-TSH Is Independent of TRH Regulation
Several lines of evidence suggest that PD-TSH and PT-TSH are
regulated through different mechanisms. In marked contrast to
PD-TSH, PT-TSH is thought to be independent of TRH regulation
because PT cells lack TRH receptor (TRHR) (Bockmann et al.,
1997). To verify this hypothesis, we measured Tshb expression
and TSHb immunoreactivity in the PD and PT of TRH null mice.
Although an amount of Tshb mRNA was detected, TSHb immu-
noreactivity was absent in the PD of TRH null mice (Figures S1B
and S1C), consistent with a previous report (Yamada et al.,
1997). In contrast, Tshb expression and TSHb immunoreactivity
were not affected by TRH deficiency in the PT (Figures S1B and
S1C), confirming that PT-TSH is independent of TRH regulation.
Circulating PT-TSH Exhibits Little Bioactivity
In mammals, photoperiodic information received by the eye is
transmitted to the pineal gland via the circadian pacemaker,
the suprachiasmatic nucleus (Reiter, 1980). Melatonin is
secreted from the pineal gland at night, and its secretion pattern
encodes the signal of night length (Reiter, 1980). Photoperiodic
regulation of TSH has been reported in the PT (Wittkowski
et al., 1988), and MT1 melatonin receptor has been observed
in PT thyrotrophs but not in the PD (Klosen et al., 2002). Further-
more, melatonin suppresses expression of Tshb in the PT via
MT1 (Ono et al., 2008; Yasuo et al., 2009). Thus, unlike PD-
TSH, PT-TSH is controlled by melatonin. To confirm this notion,
we examined the effects of melatonin on levels of TSH in the PT,
PD, and serum of C57BL mice using a radioimmunoassay (RIA).
We used C57BL mice because the effect of melatonin is more
apparent in this strain, which is genetically deficient in melatonin
synthesis, than in melatonin-proficient strains (Ebihara et al.,
1986; Ono et al., 2008). As expected, melatonin injections
decreased TSH level in the PT (Figure 1A), but had no effect on
the PD (Figure 1B). When we measured TSH level in the periph-
eral blood, we found that serum TSH was suppressed by mela-
tonin and appeared to reflect the PT-TSH profile (Figure 1C). This
result was surprising because the TSH concentration within the
PD was 10,000 times higher than that in the PT for the latter
to affect the TSH level in the peripheral blood. A series of electron
microscopic analyses revealed that PT thyrotrophs are distinct
from PD thyrotrophs (Bergmann et al., 1989; Sakamoto et al.,
2000). For example, PD thyrotrophs have numerous dense
secretory granules, whereas PT thyrotrophs have only a small
number of granules. Because PT thyrotrophs contain well-devel-
oped Golgi apparatus, large numbers of microvesicles, and
small numbers of secretory granules, they resemble hyperfunc-
tional PD thyrotrophs of thyroidectomized rat (Baker and
Yu, 1971; Bo¨ckers et al., 1995). Thus, it is believed that PT
thyrotrophs constitutively release TSH (Sakamoto et al., 2000).
Because the serum T4 concentration rises in response to TSH
(Andersen et al., 2002), we next measured the serum T4 level.
Unexpectedly, however, serum T4 levels were not influenced
by differences in serumTSH (Figure 1D), suggesting that PT-TSH
has little bioactivity in the circulation. To further confirm these
observations, we controlled the source of TSH in the circulation
by taking advantage of the differing regulatory mechanisms of
PD-TSH and PT-TSH (Figures 1E–1G). When melatonin-profi-
cient CBA mice were raised under short-day (SD) conditions,
expression of Tshb was suppressed in the PT, but not in the
PD (Figure 1E). We then gave these SD mice daily T3 injections
to suppress PD-TSH. It is well established that this T3 treatment
does not interfere with the action of TSH at the level of the TSHR
on the thyrotroph, and this method is often used to measure the
bioactivity of TSH in vivo (McKenzie, 1958; Moeller et al., 2003).
As a result, levels of Tshb mRNA and TSH were dramatically
reduced in the PD (Figures 1E and 1F). Importantly, serum TSH
level mirrored the decline in PD-TSH level (Figure 1G). We then
transferred these PD-TSH-suppressedmice to LD to induce pro-
duction of PT-TSH. Although the increase in TSH protein in the
PT was modest, probably due to the constitutive-release path-
way (Figure 1F), Tshb was markedly induced in the PT by LD
stimulus (Figure 1E), as reflected by a significant increase in
the serum TSH level under LD (Figure 1G). These results present
additional clear evidence for the existence of different mecha-
nisms that regulate PD-TSH and PT-TSH. It is important to
note that the serum T4 level, which reflects TSH bioactivity, did
not recover even after the restoration of serum TSH level by
the induction of PT-TSH by LD (Figure 1G). Taken together, these
data demonstrate that TSH of PT origin circulating peripherally
has little bioactivity.
Differential Glycosylation of the Two TSHs
To investigate the mechanism underlying the differing bioactiv-
ities of PD-TSH and PT-TSH, we first searched for possible dif-
ferences in their cDNA sequences, but found none (data not
shown). Therefore, we next performed western blotting (WB) of
PT and PD homogenates to analyze the sizes and mobilities of
TSH from each source. Under reducing conditions, PD-TSH
and bovine TSH (bTSH; used as a control) were detected as
TSHb and TSHa monomers (Figure 2A). In contrast, TSHb and
TSHa were detected in PT homogenate at molecular weight
that corresponds to the predicted size of a heterodimer (Fig-
ure 2A). These results suggested that the ability to dissociate
the heterodimer into a and b subunits differs between PT-TSH
and PD-TSH. When we examined the WB under nonreducing
conditions, all TSHs (PT-TSH, PD-TSH, and bovine) were de-
tected as heterodimers (Figure 2B). However, the molecular
weights of PT-TSH (40 kDa) and PD-TSH (37 kDa) were
different (Figure 2B). To determine the reason for this difference,
we next focused on the glycosylation of TSH. Deglycosylation by
PNGase F, which cleaves N-linked glycans, yielded immunore-
active bands with the same low molecular weight (34 kDa) for
all TSHs (Figure 2C). In contrast, O-glycanase did not affect
apparent molecular weight (Figure 2C). To further elucidate the
detailed structures of the linked oligosaccharides, we immuno-
purified TSH using antibody against TSHb. ImmunoprecipitatedC(IP)-PT-TSH was detected as two immunoreactive bands, as
shown in Figures 2B and 2D, whereas PD-TSH was detected
as a single band. Possible structures of oligosaccharides were
determined by positive-ion MALDI-TOF-MS using PNGase F-di-
gested IP-PD-TSH and IP-PT-TSH (Figure 2E). In the PD, glycans
were mainly biantennary and sulfated complexes, as previously
reported for bTSH (Wheeler and Harvey, 2001). Although
PT-TSH shared some of these biantennary N-glycans with PD-
TSH, tetra-antennary and triantennary multibranched N-glycans
associated with sialic acid were also identified in the PT. Be-
cause negatively charged sulfates affect the intensity of the pos-
itive-ion mass spectrograph (Wheeler and Harvey, 2001), we
could not quantitate the relative amount of each N-glycan in
this analysis. However, this result clearly suggested that PT-
TSH has multibranched, sialylated N-glycans. These results
were further confirmed by lectin blot (LB) analysis usingMaackia
amurensis [MAM] lectin, which recognizes Siaa2-3Galb1-
4GlcNAc, and Phaseolus vulgaris (red kidney bean) [PHA-L4]
lectin, which recognizes glycans with triantennary or greater
branching (Figure 2F). Furthermore, WB and immunohistochem-
istry demonstrated colocalization of sialyltransferase (ST3GalIV)
and TSHb only within the PT (Figures S2A and S2B). Although N-
acetylglucosaminyl-transferase V (GnT-V) was highly expressed
in the pituitary, as previously reported (Togayachi et al., 2001), its
colocalization with TSHb was only observed in the PT (Figures
S2C and S2D). All of these results suggested that tissue-specific
expression of glycosyltransferases causes the difference in oli-
gosaccharides between PD- and PT-TSH.
PT-TSH Forms the Macro-TSH Complex in the Blood
Based on the findings described above, we predicted that PT-
specific glycosylation is the cause of the low bioactivity of PT-
TSH in the peripheral circulation. This TSH can bind serum
immunoglobulin (IgG) to form a higher molecular weight complex
known as ‘‘macro-TSH’’ that has little bioactivity in humans and
rats (Klug and Adelman, 1977; Spitz et al., 1981). Therefore, we
analyzed serum TSH from SD mice and LD mice treated with
T3 (LD+T3), which contain mainly PD-TSH and PT-TSH, respec-
tively (Figures 1G and 3). In the WB of sera derived from LD+T3
mice, we observed presence of macro-TSH (Figure 3A). Using
dot blot analysis on fractions (fr) obtained from gel filtration chro-
matography, we were able to distinguish macro-TSH from free
TSH (Figure 3B). Most TSH in the serum of SD mice was in the
free form (fr 28–32; Figure 3B). In contrast, in LD+T3 mice,
macro-TSH (fr 18–22) was present along with some free TSH
(fr 26–32) (Figure 3B). The largest amount of free TSH was
observed in fractions 29 and 30 of LD+T3 and SD mice, respec-
tively. This difference was undoubtedly the result of differences
in glycosylation of PT-TSH and PD-TSH. In addition to TSH,
we measured the relative amount of IgG subclasses and IgM in
each fraction. IgG2b and IgG3 appeared to have an additional
shifted peak at fractions 19 and 20 of the LD+T3 serum, where
macro-TSH was detected (Figure 3B). To separate IgG sub-
classes that formmacro-TSH, we performed additional dot blots
using fractions collected during protein A affinity chromatog-
raphy. IgG-unbound TSH was observed in the flow-through of
fractions 1 and 2, whereas IgG-TSH complex was detected in
fractions 30, 37, and 46 (Figure 3C). Lack of these signals inell Reports 9, 801–809, November 6, 2014 ª2014 The Authors 803
Figure 2. Glycosylation Is Different be-
tween PT-TSH and PD-TSH
(A) WB of PT and PD homogenates with TSHb and
TSHa antibodies under reducing and denaturing
conditions.m, monomeric band; d, dimeric bands;
*, nonspecific bands.
(B) WB of PT and PD homogenate under nonre-
ducing conditions.
(C) Deglycosylated TSHs were analyzed under
nonreducing conditions. dgd, deglycosylated
form; arrow, glycosylated form.
(D) WB of IP-TSH under nonreducing conditions.
(E) Positive-ion MALDI-TOF-MS of N-glycans
cleaved from IP-TSHs. Blue, PD-TSH-specific N-
glycans; red, PT-TSH-specific N-glycans; purple,
common N-glycans.
(F) LB analysis of TSHs.immunodeficient NOD/SCID mice also supported the involve-
ment of IgG in the formation of macro-TSH (Figure 3C). SD
mice formed less macro-TSH than LD+T3 mice. However, they
still formed some macro-TSH with IgG when compared with
NOD/SCID mice (Figure 3C). IgG2b was detected in fractions804 Cell Reports 9, 801–809, November 6, 2014 ª2014 The Authors37 and 46, whereas IgG2a and IgG3
were observed in fraction 30 (Figure 3C).
IgG subclass isotyping revealed that
TSH bound to IgG2b was approximately
2-fold higher in LD+T3 mice than in SD
mice (Figure 3D, bottom), although its
serum concentration did not differ signif-
icantly between the two groups of ani-
mals (Figure 3D, top). Taken together,
these results suggested that PT-TSH pre-
dominantly binds IgG2b.
Based on the results presented above,
we next performed WB analysis to deter-
mine whether some serum factor(s) can
also bind PT-TSH. Indeed, addition of
serum from CBA mice to PT homogenate
decreased the relative amount of un-
bound TSH (Figure 3E). However, we
also observed absorption of PT-TSH by
the serum of immunodeficient NOD-
SCID mice (Figure 3E), indicating the ex-
istence of another TSH-binding protein
in the peripheral circulation. WB of
TSHb in IgG-depleted serum from CBA
mice (fr 2 in Figure 3C) revealed a band
of high molecular weight (100 kDa) (Fig-
ure 3F, left). We also detected a faint
band of a similar size in NOD-SCID mice
(Figure 3F, right). Although the signal in-
tensity of this TSHb band was weak, the
result was plausible because NOD-SCID
mice are known to have low serum TSH
levels (Pohlenz et al., 1999). When we
performed WB using an antibody against
albumin, we observed an immunopositivesignal in the IgG-depleted serum (fr 2 in Figure 3C) in both strains
of mice (Figure 3G). Furthermore, albumin was IP from the flow-
through (fr 2 in Figure 3C), and albumin and TSHbwere detected
by WB in both strains of mice (Figure 3H), providing additional
confirmation of the existence of an albumin-TSH complex in
the peripheral circulation. When we removed albumin from the
IgG-free flow-through (fr 2 in Figure 3C) by immunoprecipitation,
the albumin-TSH complex was no longer detectable (Figure 3I).
These results indicated that PT-TSH forms macro-TSH with
IgG or albumin. It is suggested that the binding of TSH to IgG
is extremely high in humans and rats (Erhardt and Scriba,
1977; Kourides et al., 1978; Mori et al., 1984; Sakai et al.,
2009; Vieira et al., 2006). For example, incubations with the sur-
factant Triton-X, the strong denaturants mercaptoethanol and
quinidine hydrochloride, or the enzyme trypsin do not dissociate
the IgG-TSH complex. In fact, SDS used in theWB did not disso-
ciate TSH from IgG in the present study (Figures 3A and 3F–3H).
We also examined the effect of the denaturant dithiothreitol
(DTT), which failed to dissociate the IgG-TSH complex (Fig-
ure 3J). Denaturant treatments often shift the mobility of immu-
noreactive band owing to altered protein structures. Although
the immunoreactive band of IgG-TSH was shifted by the DTT
treatment, detection of IgG2b at the same molecular weight
confirmed the existence of IgG-TSH complex even after DTT
treatment (Figure 3J). In contrast to aforementioned treatments,
only acidification below pH 3 has been reported to dissociate the
macro-TSH complex in humans (Sakai et al., 2009; Vieira et al.,
2006). Therefore, we also examined the effect of acidification
on the stability of the mouse IgG-TSH complex. However, acid-
ification at pH 3 by citrate also did not dissociate the IgG-TSH
complex (Figure 3J). These results clearly suggested that the
IgG-TSH complex is extremely stable and that PT-TSH is trap-
ped by IgG for long periods of time in circulation.
Formation of Macro-TSH Strongly Reduces Bioactivity
Glycosylation influences the bioactivity of glycoproteins (Baen-
ziger and Green, 1988; Szkudlinski et al., 2002). Therefore, we
postulated that differences in N-glycans could affect the bioac-
tivities of two TSHs. To validate this hypothesis, we examined
the bioactivities of TSH extracted from PD and PT homogenates
by the in vitro cyclic AMP accumulation assay, using Chinese
hamster ovary (CHO) cells stably expressing TSHR (Perret
et al., 1990). Unexpectedly, however, we observed no difference
in the bioactivities of PT-TSH and PD-TSH (Figure 4A), indicating
that variation in the TSH-linked N-glycans does not itself in-
fluence bioactivity. In contrast, the bioactivity of serum TSH ob-
tained from LD+T3 animals (containing PT-TSH) was lower than
that of serum TSH from SD animals (containing PD-TSH) in
both primary cultured MBH and thyrocytes (Figure 4B). When
we compared the bioactivity of free TSH (fr 30 in Figure 3B)
with macro-TSH (fr 20 in Figure 3B), the macro-TSH fraction ex-
hibited little bioactivity in primary cultures (Figure 4C). To validate
this observation, we investigated whether addition of serum to
homogenate could abolish the bioactivity of PT-TSH. Although
the addition of serum to PD homogenate had no effect, the addi-
tion of serum to PT homogenate significantly reduced the bioac-
tivity in primary cultures (Figure 4D).
DISCUSSION
Previous studies indicated that TSH secreted from the PT acts
on the adjacent ependymal cells to regulate seasonal physiology
and behavior (Hanon et al., 2008; Nakao et al., 2008; Ono et al.,C2008). In this study, we showed that PT-TSH is also detected in
the systemic circulation (Figure 1). This result was surprising
because TSH contents within the PT is 10,000-fold lower than
the contents within the PD. Constitutive release of TSH from
the PT seems to explain why we detected considerable amounts
of PT-TSH in the circulation. Furthermore, we demonstrated dif-
ferences between the oligosaccharide modifications of PD-TSH
and PT-TSH (Figure 2). Glycosylation affects the half-life of circu-
lating glycoprotein (Baenziger and Green, 1988; Strott, 2002); for
example, the short half-life (0.5–1.0 hr) of TSH is regulated by
rapid hepatic clearance. Hepatic receptors specifically interact
with sulfated TSH, resulting in a pulsatile secretion profile of
the TSH level in serum, as in the case of LH (Baenziger and
Green, 1988; Strott, 2002; Szkudlinski et al., 1993, 1995).
Although both LH and FSH are regulated by pulsatile GnRH
secretion, only LH exhibits episodic variation. This is because
FSH has sialylated N-glycan and lacks the sulfate modification,
resulting in a longer half-life (17 hr) (Wide et al., 2009). Similarly,
sialylated TSH escapes from specific receptor-mediated meta-
bolic clearance in the liver (Szkudlinski et al., 1993). Therefore,
it is possible that PT-TSH, which has multiantennary sialylated
N-glycans has a much longer half-life than PD-TSH. Indeed,
when we performed an in vitro TSH clearance assay using
mouse primary liver-cell culture, the half-life of PT-TSH
(18.7 hr, y = e0.037x) was far greater than that of PD-TSH
(1.45 hr, y = e0.479x) (Figure S3). Thus, it seems plausible that
the prolonged half-life of PT-TSH is another reason why higher
levels of PT-TSH can be detected in the serum.
Notably, patients and rodents with hypothalamic hypothy-
roidism exhibit elevated concentration of circulating TSH with
altered oligosaccharides (Beck-Peccoz et al., 1985; Helton and
Magner, 1995; Persani et al., 1998; Taylor and Weintraub,
1989). Hypothalamic hypothyroidism results in the appearance
of multiantennaryN-glycans in circulating TSH (Taylor andWein-
traub, 1989). In thyroidectomized or thyroid tumor-induced
hypothyroid mice, sulfation is reduced, and sialylation and multi-
antennary glycans were elevated in circulating TSH (DeCherney
et al., 1989; Gesundheit et al., 1986). Because expression of the
gene encoding a2-3 sialyltransferase is elevated in the PD of hy-
pothyroid mice, induction of this gene in PDmay partially explain
the increased sialylation of TSH during hypothyroidism (Helton
and Magner, 1995). However, it is possible that the serum TSH
with altered oligosaccharides observed in patients and rodents
with hypothalamic hypothyroidism could be partially derived
from the PT.
The bioactivity of PT-TSH extracted from PT homogenate was
indistinguishable from that of PD-TSH. However, formation of
macro-TSH with IgG or albumin strongly reduced the bioactivity
of PT-TSH in the systemic circulation (Figure 4). Circulating PT-
TSH formed macro-TSH predominantly via binding to IgG2b
(Figure 3). Because these results were obtained in specific path-
ogen-free animals, we propose that the IgG molecules involved
in the macro-TSH complex are naturally occurring antibodies
(NAbs). NAbs, in contrast to antibodies induced by exogenous
antigens, are physiological antibodies generated in healthy ani-
mals without prior contact to specific antigens (Lutz, 2012).
Although IgM is the primary NAb, IgG is also produced as a
NAb (Aksentijevich et al., 1991). The majority of NAbs areell Reports 9, 801–809, November 6, 2014 ª2014 The Authors 805
Figure 3. TSH Forms in the Circulation Macro-TSH with IgG or Albumin
(A) WB of serum TSH from LD+T3 mice (see Figure 1).
(B) Measurements of TSH, IgGs, and IgM in fractions from gel-filtration chromatography. Yellow shading, macro-TSH; arrow, additional peak.
(C) Separation of IgG subclasses by protein A affinity chromatography. Black open arrow, free TSH; black solid arrow, macro-TSH; red solid arrows, IgG2b; red
open arrows, IgG2a, IgG3.
(D) IgG isotyping of serum and macro-TSH.
(E) Adsorption test of TSH with serum. *p < 0.05, **p < 0.01 versus PD (means ± SEM, t test, n = 4).
(legend continued on next page)
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Figure 4. Formation of Macro-TSH Strongly Reduces Bioactivity of
PT-TSH
(A) Bioactivity of TSH from PT or PD homogenates, analyzed using TSHR-
expressing CHO cells. Ratio of TSH bioactivity to immunoreactivity (B/I) was
evaluated by cyclic AMP accumulation.
(B) Bioactivity of serum TSH from LD+T3 and SD animals, examined using
primary cultured MBH and thyrocytes.
(C) Bioactivity of macro-TSH (fr 20 of Figure 3B) and free TSH (fr 30), examined
using primary cultured MBH and thyrocytes.
(D) Effect of serum incubation on bioactivity of PT-TSH and PD-TSH. All values
are means + SEM, n = 3–5. *p < 0.05, **p < 0.01 (t test).polyclonal and therefore bind to various antigens and epitopes.
One well-known function of NAbs is the clearance of apoptotic
and damaged cells and proteins. The results of this study sug-
gest that NAbs are also involved in the functional diversification
of a hormone, TSH. In addition to IgG, PT-TSH also bound to
serum albumin. Many metabolites and drugs bind to circulating
albumin, and albumin-bound drugs often become inactive
(Mu¨ller and Wollert, 1979). Albumin is the most abundant protein
in serum and has a half-life of 19 days in humans. Therefore, it(F and G) WB of TSH (F) and albumin (G) in fractions from protein A affinity chrom
(H) Detection of IP-albumin-TSH complex in sera. Red, albumin-TSH complex; b
(I) Macro-TSH disappeared when albumin was removed from the IgG-free flow-t
(J) WB of TSHb and IgG2b in macro-TSH fractions under acidification condition (p
Cseems reasonable to conclude that the albumin-TSH complex
also contributes to the long half-life of PT-TSH in the circulation.
In this study, we demonstrated that the PT-TSH heterodimer is
more stable than the PD-TSH heterodimer (Figure 2A). We
confirmed this result under both reducing and denaturing con-
ditions (Figures S4A and S4B). Although glycosylation affects
the stability of some protein dimers (Walker et al., 2013), degly-
cosylation of PD-TSH and PT-TSH did not change the stability
profiles of the respective heterodimers (Figure S4C). Therefore,
we also investigated whether other types of modifications might
play a role in determining stability. Transglutaminases are en-
zymes that catalyze the formation of a covalent isopeptide
bond (Lorand and Graham, 2003). Among seven transglutami-
nase (Tgm) genes, we observed expression of Tgm2 in the PT.
Thus, the activity of Tgm2 may govern in the different structural
stability of PT-TSH (Figure S4D).
In summary, we showed here that tissue-specific glycosylation
prevents functional crosstalk between PT-TSH and PD-TSH.
Glycosylation is critical to a wide range of biological processes,
and the importance of tissue-specific glycosylation has come
to be recognized (Seppa¨la¨ et al., 2009). This report demonstrates
the involvement of tissue-specific glycosylation in preventing
functional crosstalk between signaling molecules in vivo.
EXPERIMENTAL PROCEDURES
Animal Experiments
This study was approved by the Committee on Animal Experiments of the
Graduate School of Bioagricultural Sciences and Research Institute of Envi-
ronmental Medicine, Nagoya University.
In Situ Hybridization
Coronal sections (20 mm thick) were prepared using a cryostat (Leica Micro-
systems, CM3050S). In situ hybridization was performed using antisense 45-
mer nucleotide probes (Table S1), as previously described (Ono et al., 2008).
Control sections were hybridized in the presence of excess unlabeled probe.
Immunohistochemistry
Immunohistochemistry to detect TSHb was performed using rabbit polyclonal
antibody to mouse/rat TSHb (1:10,000) (provided by Dr. Albert F. Parlow, the
National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]),
as previously reported (Ikegami et al., 2009) (Figure S1). For double-immuno-
fluorescence staining, PT and PD slices were incubated with rabbit polyclonal
antibody against TSHb and goat polyclonal antibody against ST3GalIV
(1:2,000) or GnT-V (1:2,000) (Santa Cruz Biotechnology) for 1 hr at room tem-
perature and then reacted with Alexa Fluor 546-conjugated donkey antigoat
IgG (1:400) and Alexa Fluor 488-conjugated goat antirabbit IgG (1:400) (Molec-
ular Probes) and mounted in DAPI/mounting medium (LK-096A, Kreatech).
RIA
Serum and tissue TSHwasmeasured using a sensitive, heterologous, disequi-
librium double-antibody precipitation RIA as previously described (Pohlenz
et al., 1999). The sensitivity of this assay was 9 mIU/L. Serum T4 concentra-
tions were measured by an antibody-coated solid phase RIA (Simens Medical
Solutions, Diagnostics) using 25 ml of serum. The sensitivity of this assay was
0.2 mg/dl.atography. Arrowhead, albumin-TSH complex.
lack, free albumin.
hrough fraction. Arrowhead, position of albumin-TSH.
H 3) by citrate or denature condition by DTT. Arrowhead, position of IgG-TSH.
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WB
WB was performed as previously reported (Ikegami et al., 2009). Membranes
were incubated with the following primary antibodies: rabbit polyclonal
antibodies against TSHb (1:10,000), TSHa (1:10,000, provided by Dr. Albert
F. Parlow, the NIDDK), and albumin (1:2,000; abcam); HRP-conjugated goat
polyclonal antibody against mouse IgG (1:20,000; abcam) and mouse IgG2b
(1:40,000; abcam); and goat polyclonal antibodies against ST3GalIV
(1:2,000) and GnT-V (1:2,000). Deglycosylation of samples was performed un-
der nonreducing conditions using GlycoPro Enzymatic Deglycosylation kit
(PROZYME), as previously reported (Zou et al., 2008).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
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AUTHOR CONTRIBUTIONS
T.Y. conceived the research. T.Y., K.I., and S.R. designed the research. K.I.,
X.L., Y.H., H.O., W.O., Y.I., and T.N.O. performed experiments and analyzed
data. M.Y., C.S., K.K., Y.M., M.I., Y.S., and T.Y. provided new materials and
advised the research. K.I, T.Y., and S.R. wrote the paper. All of the authors re-
viewed and commented on the manuscript.
ACKNOWLEDGMENTS
We thank Drs. G. Vassart, A. Iwasawa, A. Fujita, K. Kuwata, A. Yamanaka, H.
Mizoguchi, M. Itoh, and Y. Nakajima for technical support and helpful discus-
sion. We thank the Nagoya University Radioisotope Centre for use of facilities.
This work was supported by the Funding Program for Next Generation World
Leading Researchers (NEXT Program) initiated by the Council for Science and
Technology Policy (CSTP) (LS055), Grant-in-Aid for the Japan Society for the
Promotion of Science (JSPS) Fellows (22005794), JSPS KAKENHI Grant Num-
ber 26000013, WPI program, and a grant R37DK15070 from the NIH.
Received: August 4, 2014
Revised: September 4, 2014
Accepted: September 30, 2014
Published: October 30, 2014
REFERENCES
Aksentijevich, I., Sachs, D.H., and Sykes, M. (1991). Natural antibodies
against bone marrow cells of a concordant xenogeneic species. J. Immunol.
147, 79–85.
Andersen, S., Pedersen, K.M., Bruun, N.H., and Laurberg, P. (2002). Narrow
individual variations in serum T(4) and T(3) in normal subjects: a clue to the un-
derstanding of subclinical thyroid disease. J. Clin. Endocrinol. Metab. 87,
1068–1072.
Baenziger, J.U., and Green, E.D. (1988). Pituitary glycoprotein hormone oligo-
saccharides: structure, synthesis and function of the asparagine-linked oligo-
saccharides on lutropin, follitropin and thyrotropin. Biochim. Biophys. Acta
947, 287–306.
Baker, B.L., and Yu, Y.Y. (1971). Hypophyseal changes induced by thyroid
deficiency and thyroxine administration as revealed by immunochemical stain-
ing. Endocrinology 89, 996–1004.
Beck-Peccoz, P., Amr, S., Menezes-Ferreira, M.M., Faglia, G., andWeintraub,
B.D. (1985). Decreased receptor binding of biologically inactive thyrotropin in
central hypothyroidism. Effect of treatment with thyrotropin-releasing hor-
mone. N. Engl. J. Med. 312, 1085–1090.
Bergmann, M., Wittkowski, W., and Hoffmann, K. (1989). Ultrastructural local-
ization of thyrotropin (TSH)-like immunoreactivity in specific secretory cells of
the hypophyseal pars tuberalis in the Djungarian hamster, Phodopus sungo-
rus. Cell Tissue Res. 256, 649–652.808 Cell Reports 9, 801–809, November 6, 2014 ª2014 The AuthorsBo¨ckers, T.M., Niklowitz, P., Bockmann, J., Fauteck, J.D., Wittkowski, W., and
Kreutz, M.R. (1995). Daily melatonin injections induce cytological changes in
pars tuberalis-specific cells similar to short photoperiod. J. Neuroendocrinol.
7, 607–613.
Bockmann, J., Bo¨ckers, T.M., Winter, C., Wittkowski, W., Winterhoff, H., Deu-
fel, T., and Kreutz, M.R. (1997). Thyrotropin expression in hypophyseal pars tu-
beralis-specific cells is 3,5,30-triiodothyronine, thyrotropin-releasing hormone,
and pit-1 independent. Endocrinology 138, 1019–1028.
DeCherney, G.S., Gesundheit, N., Gyves, P.W., Showalter, C.R., and Wein-
traub, B.D. (1989). Alterations in the sialylation and sulfation of secretedmouse
thyrotropin in primary hypothyroidism. Biochem. Biophys. Res. Commun. 159,
755–762.
Ebihara, S., Marks, T., Hudson, D.J., and Menaker, M. (1986). Genetic control
of melatonin synthesis in the pineal gland of themouse. Science 231, 491–493.
Erhardt, F.W., and Scriba, P.C. (1977). High molecular thyrotrophin (‘‘big’’-
TSH) from human pituitaries: preparation and partial characterization. Acta
Endocrinol. (Copenh.) 85, 698–712.
Gesundheit, N., Magner, J.A., Chen, T., and Weintraub, B.D. (1986). Differen-
tial sulfation and sialylation of secreted mouse thyrotropin (TSH) subunits:
regulation by TSH-releasing hormone. Endocrinology 119, 455–463.
Hanon, E.A., Lincoln, G.A., Fustin, J.M., Dardente, H., Masson-Pe´vet, M.,
Morgan, P.J., and Hazlerigg, D.G. (2008). Ancestral TSH mechanism signals
summer in a photoperiodic mammal. Curr. Biol. 18, 1147–1152.
Helton, T.E., and Magner, J.A. (1995). b-Galactoside a-2,3-sialyltransferase
messenger RNA increases in thyrotrophs of hypothyroid mice. Thyroid 5,
315–317.
Ikegami, K., Katou, Y., Higashi, K., and Yoshimura, T. (2009). Localization of
circadian clock protein BMAL1 in the photoperiodic signal transduction ma-
chinery in Japanese quail. J. Comp. Neurol. 517, 397–404.
Klosen, P., Bienvenu, C., Demarteau, O., Dardente, H., Guerrero, H., Pe´vet, P.,
and Masson-Pe´vet, M. (2002). The mt1 melatonin receptor and RORbeta re-
ceptor are co-localized in specific TSH-immunoreactive cells in the pars tuber-
alis of the rat pituitary. J. Histochem. Cytochem. 50, 1647–1657.
Klug, T.L., and Adelman, R.C. (1977). Evidence for a large thyrotropin and its
accumulation during aging in rats. Biochem. Biophys. Res. Commun. 77,
1431–1437.
Kourides, I.A., Weintraub, B.D., and Maloof, F. (1978). Large molecular weight
TSH-b: the sole immunoactive form of TSH-b in certain human sera. J. Clin. En-
docrinol. Metab. 47, 24–33.
Lorand, L., and Graham, R.M. (2003). Transglutaminases: crosslinking en-
zymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140–156.
Lutz, H.U. (2012). Naturally Occurring Antibodies (NAbs) (Austin, TX: Landes
Bioscience/Springer Science + Business Media).
Magner, J.A. (1990). Thyroid-stimulating hormone: biosynthesis, cell biology,
and bioactivity. Endocr. Rev. 11, 354–385.
McKenzie, J.M. (1958). The bioassay of thyrotropin in serum. Endocrinology
63, 372–382.
Moeller, L.C., Kimura, S., Kusakabe, T., Liao, X.H., Van Sande, J., and Refetoff,
S. (2003). Hypothyroidism in thyroid transcription factor 1 haploinsufficiency is
caused by reduced expression of the thyroid-stimulating hormone receptor.
Mol. Endocrinol. 17, 2295–2302.
Mori, M., Ohshima, K., Fukuda, H., Kobayashi, I., and Wakabayashi, K. (1984).
Changes in the multiple components of rat pituitary TSH and TSH b subunit
following thyroidectomy. Acta Endocrinol. (Copenh.) 105, 49–56.
Mu¨ller, W.E., and Wollert, U. (1979). Human serum albumin as a ‘silent recep-
tor’ for drugs and endogenous substances. Pharmacology 19, 59–67.
Nakao, N., Ono, H., Yamamura, T., Anraku, T., Takagi, T., Higashi, K., Yasuo,
S., Katou, Y., Kageyama, S., Uno, Y., et al. (2008). Thyrotrophin in the pars tu-
beralis triggers photoperiodic response. Nature 452, 317–322.
Ono, H., Hoshino, Y., Yasuo, S., Watanabe, M., Nakane, Y., Murai, A., Ebihara,
S., Korf, H.W., and Yoshimura, T. (2008). Involvement of thyrotropin in
photoperiodic signal transduction in mice. Proc. Natl. Acad. Sci. USA 105,
18238–18242.
Perret, J., Ludgate, M., Libert, F., Gerard, C., Dumont, J.E., Vassart, G., and
Parmentier, M. (1990). Stable expression of the human TSH receptor in CHO
cells and characterization of differentially expressing clones. Biochem. Bio-
phys. Res. Commun. 171, 1044–1050.
Persani, L., Borgato, S., Romoli, R., Asteria, C., Pizzocaro, A., and Beck-Pec-
coz, P. (1998). Changes in the degree of sialylation of carbohydrate chains
modify the biological properties of circulating thyrotropin isoforms in various
physiological and pathological states. J. Clin. Endocrinol. Metab. 83, 2486–
2492.
Pierce, J.G., and Parsons, T.F. (1981). Glycoprotein hormones: structure and
function. Annu. Rev. Biochem. 50, 465–495.
Pohlenz, J., Maqueem, A., Cua, K., Weiss, R.E., Van Sande, J., and Refetoff, S.
(1999). Improved radioimmunoassay for measurement of mouse thyrotropin in
serum: strain differences in thyrotropin concentration and thyrotroph sensi-
tivity to thyroid hormone. Thyroid 9, 1265–1271.
Reiter, R.J. (1980). The pineal and its hormones in the control of reproduction in
mammals. Endocr. Rev. 1, 109–131.
Sakai, H., Fukuda, G., Suzuki, N., Watanabe, C., and Odawara, M. (2009).
Falsely elevated thyroid-stimulating hormone (TSH) level due to macro-TSH.
Endocr. J. 56, 435–440.
Sakamoto, S., Nakamura, K., Inoue, K., and Sakai, T. (2000). Melatonin stim-
ulates thyroid-stimulating hormone accumulation in the thyrotropes of the
rat pars tuberalis. Histochem. Cell Biol. 114, 213–218.
Seppa¨la¨, M., Koistinen, H., Koistinen, R., Hautala, L., Chiu, P.C., and Yeung,
W.S. (2009). Glycodelin in reproductive endocrinology and hormone-related
cancer. Eur. J. Endocrinol. 160, 121–133.
Spitz, I.M., Le Roith, D., Hirsch, H., Carayon, P., Pekonen, F., Liel, Y., Sobel, R.,
Chorer, Z., and Weintraub, B. (1981). Increased high-molecular-weight thyro-
tropin with impaired biologic activity in a euthyroid man. N. Engl. J. Med. 304,
278–282.
Strott, C.A. (2002). Sulfonation and molecular action. Endocr. Rev. 23,
703–732.
Szkudlinski, M.W., Thotakura, N.R., Bucci, I., Joshi, L.R., Tsai, A., East-
Palmer, J., Shiloach, J., and Weintraub, B.D. (1993). Purification and charac-
terization of recombinant human thyrotropin (TSH) isoforms produced by
Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioac-
tivity. Endocrinology 133, 1490–1503.
Szkudlinski, M.W., Thotakura, N.R., and Weintraub, B.D. (1995). Subunit-spe-
cific functions ofN-linked oligosaccharides in human thyrotropin: role of termi-
nal residues of a- and b-subunit oligosaccharides in metabolic clearance and
bioactivity. Proc. Natl. Acad. Sci. USA 92, 9062–9066.
Szkudlinski, M.W., Fremont, V., Ronin, C., and Weintraub, B.D. (2002). Thy-
roid-stimulating hormone and thyroid-stimulating hormone receptor struc-
ture-function relationships. Physiol. Rev. 82, 473–502.CTaylor, T., and Weintraub, B.D. (1989). Altered thyrotropin (TSH) carbohydrate
structures in hypothalamic hypothyroidism created by paraventricular nuclear
lesions are corrected by in vivo TSH-releasing hormone administration. Endo-
crinology 125, 2198–2203.
Togayachi, A., Akashima, T., Ookubo, R., Kudo, T., Nishihara, S., Iwasaki, H.,
Natsume, A., Mio, H., Inokuchi, J., Irimura, T., et al. (2001). Molecular cloning
and characterization of UDP-GlcNAc:lactosylceramide b 1,3-N-acetylgluco-
saminyltransferase (b 3Gn-T5), an essential enzyme for the expression of
HNK-1 and Lewis X epitopes on glycolipids. J. Biol. Chem. 276, 22032–22040.
Vieira, J.G.H., Maciel, R.M.B., Hauache, O.M., Nishida, S.K., Boelter, D.M.G.,
and Pinheiro, M.F.M.C. (2006). Unexpected high values of TSH: the presence
of high molecular weight forms (macro TSH) must be investigated. Arq. Bras.
Endocrinol. Metabol. 50, 445–449.
Walker, A.K., Soo, K.Y., Levina, V., Talbo, G.H., and Atkin, J.D. (2013).N-linked
glycosylation modulates dimerization of protein disulfide isomerase family A
member 2 (PDIA2). FEBS J. 280, 233–243.
Wheeler, S.F., and Harvey, D.J. (2001). Extension of the in-gel release method
for structural analysis of neutral and sialylated N-linked glycans to the analysis
of sulfated glycans: application to the glycans from bovine thyroid-stimulating
hormone. Anal. Biochem. 296, 92–100.
Wide, L., Eriksson, K., Sluss, P.M., and Hall, J.E. (2009). Serum half-life of pi-
tuitary gonadotropins is decreased by sulfonation and increased by sialylation
in women. J. Clin. Endocrinol. Metab. 94, 958–964.
Wittkowski, W., Bergmann, M., Hoffmann, K., and Pera, F. (1988). Photope-
riod-dependent changes in TSH-like immunoreactivity of cells in the hypophy-
sial pars tuberalis of the Djungarian hamster, Phodopus sungorus. Cell Tissue
Res. 251, 183–187.
Wittkowski, W., Bockmann, J., Kreutz, M.R., and Bo¨ckers, T.M. (1999). Cell
and molecular biology of the pars tuberalis of the pituitary. Int. Rev. Cytol.
185, 157–194.
Yamada, M., Saga, Y., Shibusawa, N., Hirato, J., Murakami, M., Iwasaki, T.,
Hashimoto, K., Satoh, T., Wakabayashi, K., Taketo, M.M., and Mori, M.
(1997). Tertiary hypothyroidism and hyperglycemia in mice with targeted
disruption of the thyrotropin-releasing hormone gene. Proc. Natl. Acad. Sci.
USA 94, 10862–10867.
Yasuo, S., Yoshimura, T., Ebihara, S., and Korf, H.W. (2009). Melatonin trans-
mits photoperiodic signals through the MT1 melatonin receptor. J. Neurosci.
29, 2885–2889.
Yoshimura, T., Yasuo, S., Watanabe, M., Iigo, M., Yamamura, T., Hirunagi, K.,
and Ebihara, S. (2003). Light-induced hormone conversion of T4 to T3 regulates
photoperiodic response of gonads in birds. Nature 426, 178–181.
Zou, K., Hosono, T., Nakamura, T., Shiraishi, H., Maeda, T., Komano, H., Ya-
nagisawa, K., andMichikawa, M. (2008). Novel role of presenilins in maturation
and transport of integrin b 1. Biochemistry 47, 3370–3378.ell Reports 9, 801–809, November 6, 2014 ª2014 The Authors 809
